Pfizer very quietly agrees to settle 10,000 cancer lawsuits…

What should be splashed across headlines nationwide is oddly quiet. In a muffled bombshell, Pfizer, a titan in Big Pharma, has just settled a shocking 10,000 lawsuits linked to cancer and the antacid Zantac. Yes, you heard that right—banishing heartburn could now be a deadly choice, thanks to Big Pharma. These are the same so-called “experts” who rushed to declare their sketchy COVID vaccine was perfectly safe even before it was properly tested. Now it’s clear why so many people were skeptical—and rightly so.

Big Pharma has turned marketing into an art form. They hook us with catchy jingles and fun little cartoon commercials, making their products seem almost wholesome—and, of course, totally safe. Take this old ad for Zantac as a perfect example:

Many may be wondering, how on earth can Big Pharma hide something like cancer from the public? Well, sadly, it’s easy for them. They outright lie. In addition, they manipulate and hide clinical trial data. And don’t put it past them to pay off doctors, researchers, and scientists, not to mention politicians and the media.

“Nuisance suits they just settle because it’s cheaper.
Scammers go after big pockets.”

That sort of common sense won’t slow the hysteria. The usual suspects have lit the torchs and sharpened the pitchforks.

Here’s some background on this issue from 2019:

https://www.scientificamerican.com/article/what-we-know-about-the-possible-carcinogen-found-in-zantac/

“What We Know about the Possible Carcinogen Found in Zantac
The popular heartburn drug may produce potentially unsafe levels of NDMA when its active ingredient breaks down”

A Complex Chemistry

Ranitidine has been widely used for decades. If it poses a risk to human health, how could that have gone unnoticed for so long? Light alleges that there were some limitations in early safety studies involving Zantac in the 1980s. Glaxo—a company that eventually merged into GlaxoSmithKline (GSK)—Zantac’s original manufacturer, published a study of ranitidine’s metabolites in urine in 1981, but Light says that study appears not to have looked for NDMA. Glaxo published another study in 1987 that tested the stomach contents of people taking ranitidine, concluding that there was “no significant increase” in the concentration of nitrosamines, a group of chemicals—many of them carcinogenic—that includes NDMA. But Light says the detection method used in that paper was designed for food products and does not directly measure nitrosamines. In addition, the study discarded all stomach samples that contained ranitidine because they could have “falsely high” concentrations of nitrosamines, so any NDMA produced by the breakdown of ranitidine would not have been detected.

In a statement to Scientific American, GSK says it had considered the potential formation of nitrosamines in the body—during ranitidine’s development, during its regulatory review and in subsequent studies. Scientists had hypothesized that any drugs that raised the stomach’s pH could increase the growth of bacteria that produce nitrites, which could interact with chemicals called amines to produce nitrosamines. Although several studies did find that taking ranitidine could increase the concentration of nitrites in the stomach—and at least one found a statistically significant increase in nitrosamines—that does not mean they cause cancer, GSK says. The company adds that ranitidine was not carcinogenic in studies of rodents whose diet and bacterial metabolism were similar to those of humans and claims that “extensive pharmacovigilance monitoring, regular safety reviews and substantive epidemiological studies have not linked ranitidine to raised cancer risks.”

Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.